Eugene Pietzak, MD
Bladder Cancer; Prostate Cancer; Upper Tract Urothelial Cell Carcinoma; Urinary Diversion and Reconstruction; Nerve-Sparing Techniques; Minimally Invasive and Robotic Surgery
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Pietzak accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Stony Brook University Medical School
Urology - Hospital of the University of Pennsylvania
Urologic Oncology - Memorial Sloan Kettering Cancer Center
I am a board-certified urologic surgeon who specializes in the surgical treatment of bladder cancer, prostate cancer, upper urothelial cancer (cancers that arise in the renal pelvis and ureters), and other cancers of the genitourinary system. I have expertise in a wide array of surgical techniques, including minimally invasive and robotic surgery. I see patients at the Sidney Kimmel Center for Prostate and Urologic Cancers in Manhattan and MSK Commack on Long Island.
I am committed to achieving cures while preserving quality of life through careful surgical planning and meticulous surgical technique. Whenever possible, I use nerve-sparing and function-sparing techniques to help maintain urinary and sexual function. For men with prostate cancer that requires treatment, I primarily perform robotic-assisted radical prostatectomy. For men and women with bladder cancer who require an operation to remove the bladder (radical cystectomy), I can provide expertise in advanced urinary reconstructive techniques, such as continent neobladder diversion that can re-create the natural urination pathway after bladder removal.
Because the treatment of cancers of the genitourinary system is complex, I work closely with colleagues in medical oncology, radiation oncology, radiology, and pathology to individualize each patient’s treatment approach based on their unique circumstance. I understand that a cancer diagnosis requires people to make many important and oftentimes, difficult decisions. I work with each of my patients and their families to provide as much information as possible regarding all options available to them. By using a patient-centered approach that takes into account individual preferences, I can provide the best possible outcome and quality of life following treatment for all my patients.
In addition to my surgical expertise, I am a surgeon-scientist involved in clinical trials and translational research working towards the development of new treatments for people with bladder cancer, prostate cancer, and upper tract urothelial cancer. We have a large research program focused on identifying ways to personalize and improve treatment options for people with bladder cancer. Our research has led to the development of several clinical trials available at MSK of new treatment approaches for people with bladder cancer so those participating in these trials may receive cutting-edge therapies before they are accessible nationally. The ultimate goal of our research efforts is to provide a better chance of cure and improved quality of life for our patients compared to currently available standard therapies.
I understand that a cancer diagnosis requires people to make many important, oftentimes difficult decisions. I work with each of my patients and their families to make sure they feel informed and empowered in their decision-making.
Awards and Honors
- Alpha Omega Alpha
- National Cancer Institute’s K12 Paul Calabresi Career Development Award for Clinical Oncology
- Society of Urologic Oncology/ American Urologic Association Research Scholar Award
- MSKCC Specialized Program of Research Excellence (SPORE) Career Enhancement Award in Bladder Cancer
- Bladder Cancer Advocacy Network (BCAN) Young Investigator Award
- Clinical Trials Investigated by Dr. Pietzak
- A Phase I/II Study Assessing the Addition of Gemcitabine to BCG Treatment in People with High-Grade Non-Muscle Invasive Bladder Cancer that Returned after Prior BCG
- A Phase II Study of Oral Erdafitinib in People with Recurrent Non-Invasive Bladder Cancer
- A Phase II Study of Pembrolizumab Immunotherapy Added to Gemcitabine Given into the Bladder to Treat Non-Muscle Invasive Bladder Cancer that Persists Despite BCG Therapy
- Clinical Trials Co-Investigated by Dr. Pietzak
- A Phase I Study of 2141-V11 Immunotherapy in People with Non-Muscle Invasive Bladder Cancer that Did Not Respond to Standard Treatment
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, Zehir A, Schultz N, Rosenberg JE, Bajorin DF, Dalbagni G, Al-Ahmadie H, Solit DB, Bochner BH. Eur Urol. 2017 Jun 2.
Visit PubMed for a full listing of Dr. Pietzak’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Eugene Pietzak discloses the following relationships and financial interests:
QED Therapeutics, Inc.
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.